Groupe la Francaise’s Takeda Pharmaceutical TAK Stock Holding History

Groupe la Francaise’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-115	Closed	-$10	–	751
2025 Q3	$10	Buy	+115	New	+$1.71K	﹤0.01%	771

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Groupe la Francaise's TAK Position: Q4 2025 in Review

Groupe la Francaise sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 115 shares — an estimated $10 sold.

Groupe la Francaise first reported a position in TAK in Q3 2025 and held it in 1 quarter. The position peaked at $10 in Q3 2025. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

Groupe la Francaise reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Groupe la Francaise sold 115 Takeda Pharmaceutical shares in Q4 2025, an estimated $10.
Groupe la Francaise first reported a position in Takeda Pharmaceutical in Q3 2025 and held it in 1 quarter.
Groupe la Francaise's Takeda Pharmaceutical position peaked at $10 in Q3 2025.
349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.